Equities Analysts Issue Forecasts for ESPR FY2025 Earnings

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share (EPS) estimate for Esperion Therapeutics from $0.09 to $0.21, while also predicting $0.23 EPS for FY2026.
• Despite reporting a quarterly EPS of ($0.02), Esperion exceeded the consensus estimate of ($0.17) and generated $82.39 million in revenue, significantly higher than the expected $62.55 million.
• Investment analysts have mixed ratings on Esperion, with two holding a "hold" rating and four assigning a "buy" rating, leading to a consensus rating of "Moderate Buy" with a price target of $7.00.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Esperion Therapeutics in a research note issued to investors on Wednesday, August 6th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings of $0.21 per share for the year, up from their prior forecast of $0.09. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Cantor Fitzgerald also issued estimates for Esperion Therapeutics' FY2026 earnings at $0.23 EPS.

ESPR has been the topic of several other reports. Wall Street Zen raised shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. The Goldman Sachs Group dropped their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Finally, Needham & Company LLC decreased their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $7.00.

Esperion Therapeutics Price Performance

NASDAQ ESPR traded down $0.07 on Friday, hitting $1.78. 3,506,740 shares of the stock were exchanged, compared to its average volume of 4,770,309. The business's fifty day moving average is $1.26 and its 200 day moving average is $1.31. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $3.94. The company has a market capitalization of $351.81 million, a PE ratio of -3.62 and a beta of 0.82.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.15. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. The firm had revenue of $82.39 million for the quarter, compared to analyst estimates of $62.55 million.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Nuveen LLC acquired a new position in shares of Esperion Therapeutics in the first quarter valued at about $4,446,000. Wasatch Advisors LP grew its stake in shares of Esperion Therapeutics by 4.9% in the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock valued at $53,861,000 after acquiring an additional 1,136,245 shares in the last quarter. Nuveen Asset Management LLC grew its stake in shares of Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after acquiring an additional 1,020,243 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Esperion Therapeutics by 45.1% in the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock valued at $3,586,000 after acquiring an additional 506,428 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Esperion Therapeutics by 18.6% in the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock valued at $5,399,000 after acquiring an additional 385,099 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.